Introduction
============

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality in many countries. It is currently the fourth leading cause of death in the United States and is expected to increase to the third leading cause by the year 2020 ([@b6-copd-2-609]; [@b15-copd-2-609]). Sleep related respiratory disturbances such as obstructive sleep apnea (OSA) may be present in such patients. As upper airway resistance has been shown to be increased in COPD patients during sleep when compared to wakefulness ([@b5-copd-2-609]), the overlapping with OSA is of clinical concern due to its high prevalence in the general population (24% of adult males and 9% of adult women) ([@b24-copd-2-609]; [@b18-copd-2-609]). There has been conflicting data in the literature regarding the prevalence of sleep disorder breathing in patients with COPD ([@b8-copd-2-609]; [@b14-copd-2-609]; [@b12-copd-2-609]). A possible source of this controversy may relate to the technical difficulties involved in obtaining accurate data from monitoring sleep systems. One recent, large scale study evaluating data from the Sleep Heart Health Study (SHHS) found no association between mild obstructive airway disease and OSA ([@b21-copd-2-609]). However, most of the data published in the literature was acquired using a thermistor or a thermocouple f or monitoring respiratory flow. Recent studies have demonstrated that these techniques may miss 25%--50% of respiratory events when compared to gold standard techniques, such as esophageal manometry ([@b19-copd-2-609]). Therefore, studies using less accurate respiratory monitoring techniques may miss or underreport respiratory events. Given the underlying pathophysiology of obstructive airway disease and the increased upper airway resistance seen during sleep, COPD patients are at risk for developing obstructive respiratory disturbance during sleep. Likewise, more subtle respiratory abnormalities, such as respiratory-effort related arousal (RERA) are associated with nocturnal cortical arousals and sleep fragmentation leading to subsequent daytime fatigue and somnolence. These events have not previously been evaluated in COPD patients. Because of the lack of an adequate non-invasive technique to monitor respiratory flow during sleep, the prevalence of respiratory disturbance associated with COPD is still uncertain.

Furthermore, COPD patients frequently complain of poor sleep quality and inadequate sleep ([@b7-copd-2-609]; [@b9-copd-2-609]). Some of the factors leading to sleep disruption in COPD patients may also be related to the worsening of respiratory function during sleep, which may result from nocturnal hypoventilation, ventilation-perfusion mismatch, and decreased functional residual capacity. Though decreases in nocturnal oxyhemoglobin saturation (SaO~2~) may occur during sleep in COPD patients, the episodes tend to be more pronounced during rapid eye movement (REM) stages of sleep due to loss of peripheral muscle tone and a functional dependence on an impaired flattened diaphragm ([@b10-copd-2-609]; [@b22-copd-2-609]; [@b13-copd-2-609]).

The nasal cannula/pressure transducer system has been considered the best non-invasive method to detect minimal changes in airflow during nocturnal polysomnogram ([@b4-copd-2-609]; [@b11-copd-2-609], 2004; [@b17-copd-2-609]; [@b23-copd-2-609]) and has also been validated to detect RERA events ([@b4-copd-2-609]). In this study, we used the nasal cannula/pressure transducer system to evaluate respiratory events and oxyhemoglobin desaturation in COPD patients without evidence of daytime hypoxemia referred for evaluation of sleep-disordered breathing. Our study compared a group of patients with COPD without daytime hypoxemia (PaO~2~ \> 60 mmHg) to a non-COPD control group, matched for BMI and age, during an attended overnight sleep study.

Methods
=======

Twenty-eight subjects were recruited during a one-year period from the Manhattan Veterans Administration Sleep Clinic. Participation in this study was offered to all subjects with a known history of COPD and absence of daytime hypoxemia who were referred to the clinic for evaluation of snoring. For each COPD subject, a control subject without COPD, matched for BMI and age was selected from the clinic pool of patients that were evaluated within the 6-week period that followed inclusion of each COPD subject. COPD was defined using the Global Initiative for Obstructive Lung Disease (GOLD) criteria ([@b20-copd-2-609]). All COPD patients had evidence of adequate oxygenation (PaO~2~ \> 60 mmHg) during wakefulness. Exclusion criteria were: (1) current or past use of continuous positive airway pressure, bi-level or supplemental oxygen; (2) respiratory failure requiring hospitalization within the previous 8-weeks; and (3) diagnosis of anemia. For each control subject, pulmonary function test was performed to rule out obstructive airway pathology.

All patients underwent spirometry while in sitting position within 6-months of the study inclusion date. An arterial blood gas sampling was performed in all COPD subjects during wakefulness, at rest in sitting position to verify adequate oxygenation. The room air oxyhemoglobin saturation (RA) SaO~2~), FEV~1~ and FEV~1~/FVC were recorded during spirometry. Subsequently, all patients were administered the Epworth Sleepiness Scale (ESS) in order to assess daytime sleepiness ([@b16-copd-2-609]). Twenty six subjects (13 with COPD and 13 non-COPD controls) completed the sleep study. An attended nocturnal polysomnography was performed in all patients at their approximate routine sleeping hours. Recorded channels included electroencephalogram (C3/A2, C4/A1, O1/A2, 02/A1), bilateral electrooculogram (EOG), submental and anterior tibialis electromyogram (EMG), EKG, rib cage and abdominal motion by inductive plethysmography, body position, nasal cannula/pressure transducer system for respiratory monitoring (Protech^®^, Woodenville, WA) and oximetry with digital signal extraction (Masimo^®^, Irvine, CA). This oximetry technology was chosen because it is based on real time acquisition and processing of SaO~2~ data and because it has improved detection in states of low perfusion, motion, and weak signal. Sleep data was recorded via Bio-logic^®^ (Mundelein, IL). Standard Rechtschaffen and Kales criteria were used to score sleep; arousals and respiratory events were scored using the [@b1-copd-2-609]. Respiratory events consisted of apneas, defined as a reduction in air flow = 90% associated with sustained chest and abdominal effort, hypopneas, defined as a reduction in air flow = 50% associated with sustained chest and abdominal effort, and RERA events, defined as inspiratory flow limitation events followed by an EEG arousal which was not associated with any other sleep disturbance. The apnea-hypopnea index (AHI) included obstructive apneas and hypopneas linked to oxyhemoglobin drop = 4%. The respiratory disturbance index (RDI) consisted of the addition of the RERA hourly index to the AHI. All subjects signed an informed consent form and the study was approved by the IRB and GCRC.

Statistical analysis
--------------------

All respiratory events were tabulated (apnea, hypopnea, and RERA) and calculated to a final hourly index of events. Respiratory events were tabulated as both AHI and RDI. Other sleep variables included total sleep time (TST) and sleep efficiency (SE). Decreases in oxyhemoglobin saturation were tabulated as follows: (1) percentage of sleep time at SaO~2~ \< 90% (TST% \< 90); (2) total sleep time (min) at SaO~2~ \< 90% (TSTmin \<90); and (3) lowest SaO~2~ level recorded during wake, and REM and non-REM stages of sleep.

The variables were examined for deviations from normality, and appropriate transformations were performed prior to analyses to satisfy model assumptions, whenever applicable. The sleep data were analyzed using SPSS^®^ software. Paired t-tests and Pearson's correlation coefficients were used for descriptive analyses. Confidence intervals were calculated for each study variable for COPD and control subjects and for the pairwise differences between groups. Linear regression analysis was used to build prediction models and p-values of 0.05 (two-sided) were used for statistical significance (with no adjustments for multiplicity).

Results
=======

Twenty-eight subjects were recruited from the Manhattan Veterans Affairs Sleep Clinic to participate in this study. Two subjects who did not complete the overnight sleep study were excluded from analyses. A total of 13 subjects with a known history of COPD and absence of daytime hypoxemia and 13 control subjects without COPD were included in the analyses. All subjects were male.

Sleep apnea
-----------

[Table 1](#t1-copd-2-609){ref-type="table"} summarizes the study variables and the pairwise differences between COPD subjects and control subjects. Nocturnal attended polysomnography detected OSA as defined by AHI \>5 events/hour in all subjects and controls. The AHI in COPD subjects was lower by an average of 13 events/hour when compared to control subjects, despite their similar age and BMI ([Figure 1](#f1-copd-2-609){ref-type="fig"}). This difference was not statistically significant. The mean AHI of the COPD subjects was 38.2 events/hour (95% CI: 23.7--54.5) vs 51.7 events/hour (95% CI: 33.4--70.8) in the control subjects (p-value not significant).

The RDI in COPD subjects was lower by an average of 13.5 events/hour as compared to control subjects during non-REM sleep and by an average of 6.3 events/hour as compared to control subjects during REM sleep. The mean non-REM RDI in COPD subjects was 40.2 events/hour (95% CI: 25.5--57.4) vs 53.6 events/hour (95% CI: 36.7--71.7) in control subjects. The mean REM RDI in COPD subjects was 44.9 events/hour (95% CI: 32.5--58.4) vs 51.3 events/hour (95% CI: 35.8--65.9) in control subjects. However, these differences were not statistically significant. In addition, RERA events did not differ significantly between the two groups. The mean RERA index in COPD subjects was 2.69 events/hour (95% CI: 1.33--4.23) vs 2.18 events/hour (95% CI: 0.48--4.85) in control subjects.

Nocturnal hypoventilation
-------------------------

Hypoxemia during sleep, as defined by the percentage of sleep time spent at SaO~2~ levels below 90%, was similar between groups as seen in [Figure 2](#f2-copd-2-609){ref-type="fig"}. Additional measurements of nocturnal hypoxemia and oxyhemoglobin saturation during sleep and wakefulness were also not statistically significant between groups, as shown in [Figure 3](#f3-copd-2-609){ref-type="fig"}.

The severity of sleep apnea as measured by AHI was a significant predictor of the TST% \< 90 in the control group (r = 0.61, p \< 0.05). However, the association between TST% \< 90 and sleep apnea was not significant in the COPD group (r = −0.15, p = ns). In the linear regression model, after controlling for BMI and FVC that could potentially confound the association of AHI and TST% \< 90, AHI was still a significant predictor of TST% \< 90 in the control group. After backward elimination, AHI and COPD status were the only variables remaining in the model and this model was significant (r = 0.66, p \< 0.05).

Other sleep variables
---------------------

The mean sleep duration was increased in the COPD group by 38 minutes (95% CI for the difference: −100, 18.5), with a tendency towards a higher sleep efficiency (by 8%, 95% CI: −21.9, 4.80), when compared to the control subjects. However, those differences were not statistically significant. Sleep efficiency was negatively associated with (RA) SaO~2~ (r = −0.70, p = 0.01) in the control group. The arousal index, as measured by total number of EEG arousals divided by the TST in hours was similar between groups.

The assessment of daytime somnolence by the ESS demonstrated a tendency to slightly higher scores in control subjects when compared to COPD subjects (difference: 2.8 points \[−0.62, 6.38\]). However, this difference was not statistically significant. Of note, the ESS score was not predictive of the severity of sleep apnea in either group. All subjects had scores above 7 (range 7--23), which is lower than the cutoff commonly used for inclusion in sleep apnea research studies (ESS = 11).

Body mass index (BMI) was a significant predictor of the severity of OSA in all subjects as shown in [Figure 4](#f4-copd-2-609){ref-type="fig"} (r = 0.60 and 0.75, for COPD and control patients respectively, p \< 0.05).

There was no significant association between BMI and lowest saturation in NREM sleep in either COPD patients or control subjects. The lowest saturation in REM sleep was negatively correlated with REM RDI in the control group (r = −0.67, p = 0.02). However, this association was not seen in the COPD subjects (r = −0.12), implying that other mechanisms controlling oxygen saturation levels may be present during REM sleep in COPD patients.

There was an inverse relationship in all subjects between severity of COPD by FEV/FVC ratio and BMI (r = −0.66, p \< 0.02), which was clinically confirmed by findings of muscle wasting in patients with more severe lung disease. Nonetheless, the severity of sleep apnea in COPD subjects was strongly associated with the severity of lung disease, measured by the FEV/FVC ratio (r = −0.85, p \< 0.001).

Discussion
==========

The objective of this study was to compare the magnitude and specific features of OSA and nocturnal hypoventilation in an unselected sample of COPD patients without daytime hypoxemia presenting to a sleep clinic for complaints of possible sleep apnea. A control group of age and BMI-matched subjects without COPD was used for comparison. Our data demonstrated that COPD without daytime hypoxemia is not associated with increased severity of sleep apnea or nocturnal hypoxemia. In fact, most COPD subjects without daytime hypoxemia had similar to lower degrees of sleep apnea than control subjects without COPD. However, the patients with more severe COPD also had severe sleep apnea. The rate of less severe events, such as RERA was the same in both groups. This is concurrent to findings described by other investigators using different respiratory monitoring techniques ([@b21-copd-2-609]; [@b3-copd-2-609]). In the present study, the mean AHI of COPD subjects was 38.2 events/hour vs 51.7 events/hour in the control subjects. This result is similar to that published by Sanders et al who demonstrated a lower index of sleep apnea severity in COPD subjects that could not be explained by changes in BMI when compared to control subjects ([@b21-copd-2-609]).

Interestingly, the effects of obesity on sleep apnea in COPD patients seem to be different than in control subjects. In fact, COPD patients may be protected against the effects of obesity on upper airway function, when compared to non-COPD patients. In this study, BMI was a much stronger predictor of sleep apnea severity in control subjects compared to COPD subjects. REM-related events and oxygen desaturation during sleep were not dependent on AHI or obesity in COPD subjects. These findings imply that other mechanisms may be the driving factors leading to respiratory disturbance and hypoxemia during sleep in COPD patients. These mechanisms may correlate to changes in ventilation/perfusion and altered mechanisms of respiratory control, which are difficult to document with standard clinical testing. As compared to control subjects, COPD subjects showed decreases in oxygen saturation during sleep that were independent of sleep apnea.

Subjects with COPD demonstrated adequate sleep duration and efficiency. The levels of daytime sleepiness were similar in both groups, as all subjects tested positive for sleep apnea. Interestingly, the ESS score was not predictive of sleep apnea or lung disease severity, with all subjects scoring above 7 on the scale. Some of the limitations of this study included the small sample size and the absence of females, which will limit our conclusions about COPD to subjects in settings that are similar to this VA-based sleep clinic population.

Conclusion
==========

This study's findings demonstrate that mild COPD is not associated with increased severity of sleep apnea or nocturnal hypoxemia. Due to the fact that those factors in COPD do not appear to correlate with obesity, other mechanisms might be involved. The present findings provide no basis for managing patients with COPD without daytime hypoxemia any differently than patients without lung disease in respect to sleep apnea evaluation.

COPD does not appear to be a risk factor that magnifies the severity of sleep apnea in COPD patients without daytime hypoxemia, regardless of the COPD severity. These findings along with other published data in the literature set the stage for a more in depth future study of the incidence of OSA and other respiratory disturbances during sleep in COPD patients across the full spectrum of disease severity in patients with chronic lung disease.
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###### 

Baseline characteristics of all subjects by group

                                               **Total**   **COPD**   **Non-COPD controls**                                       
  -------------------------------------------- ----------- ---------- ----------------------- ---- -------- ------- ---- -------- --------
  Age (yrs)                                    26          63.88      10.74                   13   63.54    10.91   13   64.23    11.01
  Body Mass Index (kg/m^2^)                    26          31.31      5.03                    13   30.85    5.32    13   31.77    4.88
  TST (min)                                    26          318.96     90.51                   13   338.31   51.80   13   299.62   116.50
  SE (%)                                       26          71.81      16.39                   13   75.71    10.88   13   67.90    20.21
  RDI (events/hour)                            26          47.40      31.55                   13   40.92    29.57   13   53.88    33.29
  AHI (events/hour)                            26          44.97      32.56                   13   38.23    30.23   13   51.70    34.60
  RERA (events/hour)                           26          2.43       3.71                    13   2.68     2.91    13   2.18     4.47
  Non-REM RDI (events/hour)                    26          46.88      32.30                   13   40.16    30.64   13   53.60    33.71
  REM RDI (events/hour)                        24          48.09      26.36                   12   44.92    24.18   12   51.27    29.08
  Awake mean SaO~2~ (% Hgb)                    26          94.03      2.30                    13   94.09    2.03    13   93.97    2.63
  Mean SaO~2~ during sleep (% Hgb)             26          93.19      2.57                    13   93.35    1.98    13   93.03    3.12
  TST at SaO~2~ \< 90% (min)                   26          33.38      52.79                   13   28.42    23.67   13   38.33    72.05
  Percentage of TST at SaO~2~ \< 90% (% Hgb)   26          11.08      14.94                   13   8.10     6.60    13   14.07    20.05
  Lowest SaO~2~ during non-REM sleep (% Hgb)   26          77.27      9.21                    13   79.62    8.19    13   74.92    9.89
  Lowest SaO~2~ during REM sleep (% Hgb)       24          81.08      10.01                   12   81.50    9.41    12   80.67    10.98
  FEV~1~ (liters)                              26          2.55       0.80                    13   2.30     0.79    13   2.80     0.75
  FVC (liters)                                 26          3.53       1.03                    13   3.59     1.08    13   3.46     1.02
  FEV~1~(% predicted)                          26          75.77      20.1                    13   66.77    18.27   13   84.77    18.33
